-
The Global Fund has signed a letter of intent with Pfizer for the procurement of up to 6 million treatment courses of the new oral antiviral medicine nirmatrelvir/ritonavir, sold under the name PAXLOVID™, in 2022-2023.
-
The Global Fund to Fight AIDS, Tuberculosis and Malaria applauds the decision by New Zealand to contribute NZ$8 million to the Global Fund's COVID-19 Response Mechanism (C19RM). The new funding will help provide lifesaving diagnostic tests, treatment...
-
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria held its 47th Board meeting this week in Geneva. A few months ahead of the Global Fund’s Seventh Replenishment Conference to be hosted by the United States, the Board renewed its ca...
-
The Global Fund to Fight AIDS, Tuberculosis and Malaria thanks the European Union and Team Europe for their contribution to the Global Fund's COVID-19 Response Mechanism (C19RM). The President of the European Commission, Ursula von der Leyen, announc...
-
The Global Fund, the United States and Unitaid, together with FIND and other ACT-Accelerator partners, are launching over US$120 million in support to countries for test-and-treat programs to prevent hospitalizations and deaths from COVID-19 for thos...
-
Ahead of World Malaria Day, 25 April, the Global Fund calls for renewed commitment in the fight against malaria, a disease that now kills one child every minute. After years of steady declines, malaria cases and deaths are on the rise mainly due to s...
